It means Tlab keeps landing overseas contracts as it continues to expand its revenue source internationally. Nothing has changed, and the market will only react to this company if it demonstrates an outstanding quarter without sequential domestic decline and/or impingement/drawdown of the cash assets. The R&D capex must be relative to growth, because increased sales success is the key to the short term change in this company at this time. Efforts should be on sales - getting larger contracts and getting US domestic back is the quickist route to investor interest and higher stock prices. SALES AND MARKETING can drive this company, as the R&D is in place to promote. Soon, the R&D expense will ultimately have to become relative, so now is the time to market it and cash in.
Call investor relations,maybe they will tell the importance of the deal,honestly i highly dout it from these thieves and crooks,where have the shares went from the news release..nowhere thats the importance of the deal,thats my take on it!